Cue Biopharma shares surge 20.77% after-hours after reporting $21.9M Q4 collaboration revenue and 40% stake in ImmunoScape.

Cue Biopharma surged 20.77% in after-hours trading following the release of its Q4 and full-year 2025 financial results, which highlighted $21.9M in collaboration revenue from its partnership with ImmunoScape, $27.1M in cash reserves, and a 40% equity stake in the partner. The company also reported a Q4 EPS of $0.01, surpassing the estimated $0.10 loss, and outlined progress on its lead autoimmune candidate, CUE-401. These developments, including robust revenue growth, improved liquidity, and strategic equity gains, aligned with the stock’s sharp post-market rally, reflecting investor optimism about its financial stability and pipeline advancements.